Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 311-323

  dos Santos, Luara Isabela ^a,b   Galvão Filho, Bruno ^a,b   de Faria, Paula Cristina ^a   Junqueira, Caroline ^a,b   Dutra, Miriam Santos ^a,b   Teixeira, Santuza Maria Ribeiro ^b   Rodrigues, Maurício Martins ^c   Ritter, Gerd ^d   Bannard, Oliver ^e   Fearon, Douglas Thomas ^f   Antonelli, Lis Ribeiro ^a   Gazzinelli, Ricardo Tostes ^a,b,g  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Anti CTLA 4; Cancer; Immunotherapy; NY ESO 1; Trypanosoma cruzi

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA; L SELECTIN; LIVE VACCINE; NY ESO 1 ANTIGEN; PROTOZOAL VACCINE; RECOMBINANT PROTEIN; CTAG1B PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL POPULATION; CELL SUBPOPULATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC LYMPHOCYTE; DOWN REGULATION; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LYMPHOCYTE MIGRATION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRYPANOSOMA CRUZI; TUMOR GROWTH; VACCINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; PARASITOLOGY; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; FEMALE; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TRYPANOSOMA CRUZI;

EID: 84925537115     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1634-8     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208
2. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915. doi:10.1038/nm1100
3. Chen J, Zhang L, Wen W, Hao J, Zeng P, Qian X, Zhang Y, Yin Y (2012) Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice. PLoS One 7(10):e47219. doi:10.1371/journal.pone.0047219
4. Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10:3. doi:10.1186/1476-4598-10-3
5. Junqueira C, Guerrero AT, Galvao-Filho B, Andrade WA, Salgado AP, Cunha TM, Ropert C, Campos MA, Penido ML, Mendonca-Previato L, Previato JO, Ritter G, Cunha FQ, Gazzinelli RT (2012) Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLoS One 7(5):e36245. doi:10.1371/journal.pone.0036245
6. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94(5):1914–1918
7. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, Neville AM (2011) Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 6(3):e17876. doi:10.1371/journal.pone.0017876
8. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92(6):856–860. doi:10.1002/ijc.1282
9. Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J (2011) Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX. Cancer Immunol Immunother 60(11):1625–1637. doi:10.1007/s00262-011-1041-3
10. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jager E (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 109(15):5797–5802. doi:10.1073/pnas.1117208109
11. Junqueira C, Santos LI, Galvao-Filho B, Teixeira SM, Rodrigues FG, DaRocha WD, Chiari E, Jungbluth AA, Ritter G, Gnjatic S, Old LJ, Gazzinelli RT (2011) Trypanosoma cruzi as an effective cancer antigen delivery vector. Proc Natl Acad Sci USA 108(49):19695–19700. doi:10.1073/pnas.1110030108
12. Martin DL, Weatherly DB, Laucella SA, Cabinian MA, Crim MT, Sullivan S, Heiges M, Craven SH, Rosenberg CS, Collins MH, Sette A, Postan M, Tarleton RL (2006) CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2(8):e77. doi:10.1371/journal.ppat.0020077
13. Padilla AM, Bustamante JM, Tarleton RL (2009) CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol 21(4):385–390. doi:10.1016/j.coi.2009.07.006
14. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L (2012) Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 189(7):3759–3766. doi:10.4049/jimmunol.1201529
15. Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjolander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A (2004) NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1 + tumors. Clin Cancer Res 10(8):2879–2890
16. DaRocha WD, Silva RA, Bartholomeu DC, Pires SF, Freitas JM, Macedo AM, Vazquez MP, Levin MJ, Teixeira SM (2004) Expression of exogenous genes in Trypanosoma cruzi: improving vectors and electroporation protocols. Parasitol Res 92(2):113–120. doi:10.1007/s00436-003-1004-5
17. Streeck H, Frahm N, Walker BD (2009) The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 4(4):461–469. doi:10.1038/nprot.2009.7
18. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H (2010) Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16(10):2781–2791. doi:10.1158/1078-0432.CCR-09-3243
19. Atayde VD, Neira I, Cortez M, Ferreira D, Freymuller E, Yoshida N (2004) Molecular basis of non-virulence of Trypanosoma cruzi clone CL-14. Int J Parasitol 34(7):851–860. doi:10.1016/j.ijpara.2004.03.003
20. Bixby LM, Tarleton RL (2008) Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol 181(4):2644–2650. doi:10.4049/jimmunol.181.4.2644
21. Huster KM, Busch V, Schiemann M, Linkemann K, Kerksiek KM, Wagner H, Busch DH (2004) Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci USA 101(15):5610–5615. doi:10.1073/pnas.0308054101
22. Barber DL, Wherry EJ, Ahmed R (2003) Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 171(1):27–31
23. Bannard O, Kraman M, Fearon DT (2009) Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science 323(5913):505–509. doi:10.1126/science.1166831
24. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6(4):e19499. doi:10.1371/journal.pone.0019499
25. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107(9):4275–4280. doi:10.1073/pnas.0915174107
26. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695–1710. doi:10.1084/jem.20130579
27. Nasman A, Romanitan M, Nordfors C, Grun N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T, Ramqvist T (2012) Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 7(6):e38711. doi:10.1371/journal.pone.0038711
28. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15):1949–1955. doi:10.1200/JCO.2010.30.5037
29. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1(1):32–42. doi:10.1158/2326-6066.CIR-13-0013
30. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y (1995) A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med 1(5):471–477
31. Moreno M, Kramer MG, Yim L, Chabalgoity JA (2010) Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther 10(1):56–76
32. Roskin G (1946) Toxin therapy of experimental cancer; the influence of protozoan infections upon transplanted cancer. Cancer Res 6:363–365
33. Klyueva NG, Roskin G (1946) Cancerolytic substance of Schizotrypanum cruzi. Am Rev Sov Med 4(2):127–129
34. Hauschka TS, Goodwin MB (1948) Trypanosoma cruzi endotoxin (KR) in the treatment of malignant mouse tumors. Science 107(2788):600–602. doi:10.1126/science.107.2788.600
35. Lima MT, Lenzi HL, Gattass CR (1995) Negative tissue parasitism in mice injected with a noninfective clone of Trypanosoma cruzi. Parasitol Res 81(1):6–12
36. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2(4):293–299. doi:10.1038/86297
37. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195(10):1279–1288
38. Bartholomeu DC, Ropert C, Melo MB, Parroche P, Junqueira CF, Teixeira SM, Sirois C, Kasperkovitz P, Knetter CF, Lien E, Latz E, Golenbock DT, Gazzinelli RT (2008) Recruitment and endo-lysosomal activation of TLR9 in dendritic cells infected with Trypanosoma cruzi. J Immunol 181(2):1333–1344
39. Caetano BC, Carmo BB, Melo MB, Cerny A, dos Santos SL, Bartholomeu DC, Golenbock DT, Gazzinelli RT (2011) Requirement of UNC93B1 reveals a critical role for TLR7 in host resistance to primary infection with Trypanosoma cruzi. J Immunol 187(4):1903–1911. doi:10.4049/jimmunol.1003911
40. Kaech SM, Ahmed R (2001) Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2(5):415–422. doi:10.1038/87720
41. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4(3):225–234. doi:10.1038/ni889
42. Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H, Busch DH (2007) A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 27(6):985–997. doi:10.1016/j.immuni.2007.10.012
43. Corse E, Allison JP (2012) Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 189(3):1123–1127. doi:10.4049/jimmunol.1200695
44. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466
45. Dillard T, Yedinak CG, Alumkal J, Fleseriu M (2010) Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13(1):29–38. doi:10.1007/s11102-009-0193-z
46. Heger M (2012) Cancer immunotherapy shows promise in multiple tumor types. Nat Med 18(7):993. doi:10.1038/nm0712-993
47. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Goppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8(1):e53745. doi:10.1371/journal.pone.0053745
48. Hurwitz AA, Yu TF, Leach DR, Allison JP (1998) CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95(17):10067–10071
49. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935–1945. doi:10.1172/JCI27745
50. Martins GA, Tadokoro CE, Silva RB, Silva JS, Rizzo LV (2004) CTLA-4 blockage increases resistance to infection with the intracellular protozoan Trypanosoma cruzi. J Immunol 172(8):4893–4901